Post by 9amHealth

📣 We’ve raised a $26M Series B to take on one of the biggest challenges in healthcare: the majority of employer pharmacy spend. We started in cardiometabolic care, helping people living with obesity, diabetes, and related conditions get better care, while supporting employers in managing rising costs driven by therapies like GLP-1s. Now, we’re building on that foundation. With this Series B, led by Define Ventures and joined by SemperVirens VC, Catalio Capital Management, and NewHealth Ventures, we’re expanding beyond cardiometabolic care to address a broader set of high-cost, complex chronic conditions accounting for the majority of employer medication spend. These conditions often require ongoing specialty medications, continuous care, and better coordination across the system. We believe the future isn’t point solutions—it’s integrated platforms that can manage entire populations and deliver both better outcomes and lower costs. We’re grateful to our investors, partners, and team for making this possible. 👉Read the full press release here: https://lnkd.in/gZUhjxZd